<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Chapter 2 Cerebrovascular | Vascular Surgery Board Review</title>
  <meta name="description" content="This is a ebook version of board review content produece on Audible Bleeding" />
  <meta name="generator" content="bookdown 0.24 and GitBook 2.6.7" />

  <meta property="og:title" content="Chapter 2 Cerebrovascular | Vascular Surgery Board Review" />
  <meta property="og:type" content="book" />
  
  
  <meta property="og:description" content="This is a ebook version of board review content produece on Audible Bleeding" />
  <meta name="github-repo" content="rstudio/bookdown-demo" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Chapter 2 Cerebrovascular | Vascular Surgery Board Review" />
  
  <meta name="twitter:description" content="This is a ebook version of board review content produece on Audible Bleeding" />
  

<meta name="author" content="Audible Bleeding" />


<meta name="date" content="2022-01-23" />

  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="index.html"/>
<link rel="next" href="references.html"/>
<script src="libs/header-attrs-2.11/header-attrs.js"></script>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.0.1/anchor-sections.js"></script>




<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">VS Board Review</a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> About</a>
<ul>
<li class="chapter" data-level="1.1" data-path="index.html"><a href="index.html#usage"><i class="fa fa-check"></i><b>1.1</b> Usage</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="cerebrovascular.html"><a href="cerebrovascular.html"><i class="fa fa-check"></i><b>2</b> Cerebrovascular</a>
<ul>
<li class="chapter" data-level="2.1" data-path="cerebrovascular.html"><a href="cerebrovascular.html#available-guidelines"><i class="fa fa-check"></i><b>2.1</b> Available Guidelines</a></li>
<li class="chapter" data-level="2.2" data-path="cerebrovascular.html"><a href="cerebrovascular.html#presentation-and-diagnosis"><i class="fa fa-check"></i><b>2.2</b> Presentation and Diagnosis</a></li>
<li class="chapter" data-level="2.3" data-path="cerebrovascular.html"><a href="cerebrovascular.html#management"><i class="fa fa-check"></i><b>2.3</b> Management</a>
<ul>
<li class="chapter" data-level="2.3.1" data-path="cerebrovascular.html"><a href="cerebrovascular.html#optimal-medical-therapy"><i class="fa fa-check"></i><b>2.3.1</b> <strong>Optimal medical therapy</strong></a></li>
<li class="chapter" data-level="2.3.2" data-path="cerebrovascular.html"><a href="cerebrovascular.html#carotid-endarterectomy"><i class="fa fa-check"></i><b>2.3.2</b> <strong>Carotid endarterectomy</strong></a></li>
<li class="chapter" data-level="2.3.3" data-path="cerebrovascular.html"><a href="cerebrovascular.html#carotid-artery-stenting"><i class="fa fa-check"></i><b>2.3.3</b> Carotid Artery Stenting</a></li>
<li class="chapter" data-level="2.3.4" data-path="cerebrovascular.html"><a href="cerebrovascular.html#management-of-uncommon-disease-presentations"><i class="fa fa-check"></i><b>2.3.4</b> Management of uncommon disease presentations</a></li>
</ul></li>
<li class="chapter" data-level="2.4" data-path="cerebrovascular.html"><a href="cerebrovascular.html#prospective-trials---must-reads"><i class="fa fa-check"></i><b>2.4</b> Prospective Trials - MUST READS</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="references.html"><a href="references.html"><i class="fa fa-check"></i>References</a></li>
<li class="divider"></li>
<li><a href="https://github.com/adam-mdmph/VS-Board-Review" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Vascular Surgery Board Review</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="cerebrovascular" class="section level1" number="2">
<h1><span class="header-section-number">Chapter 2</span> Cerebrovascular</h1>
<p><strong>07 Jan 2019:</strong> <em>Adam Johnson, MD, MPH; Nicole Rich, MD, MPH; Kevin
Kniery, MD, MPH</em></p>
<p><audio controls> <source src='https://traffic.libsyn.com/audiblebleeding/E7_-_Carotid_VSITE.mp3' type='audio/mpeg'> Your browser does not support the audio tag;  for browser support, please see:  https://www.w3schools.com/tags/tag_audio.asp </audio></p>
<div id="available-guidelines" class="section level2" number="2.1">
<h2><span class="header-section-number">2.1</span> Available Guidelines</h2>
<p><a href="https://www.jvascsurg.org/article/S0741-5214%2811%2901635-1/fulltext">Updated Society for Vascular Surgery guidelines for management of
extracranial carotid
disease</a></p>
</div>
<div id="presentation-and-diagnosis" class="section level2" number="2.2">
<h2><span class="header-section-number">2.2</span> Presentation and Diagnosis</h2>
<ol style="list-style-type: decimal">
<li><p><strong>What is the definition of crescendo TIAs?</strong></p>
<p>Frequent repetitive neurological attacks without complete resolution
of the deficit between the episodes, producing the same deficit but
no progressive deterioration in neurological function If a
progressive deterioration then it is a stroke in evolution.</p></li>
<li><p><strong>Who needs to be screened?</strong></p>
<p>Only 15% of stroke victims have a warning TIA before a stroke so
waiting until symptoms occur is not ideal. The purpose of carotid
bifurcation imaging is to detect “stroke-prone” carotid bifurcation
plaque and identify a high-risk patient likely to benefit from
therapy designed to reduce stroke risk.</p>
<p>The absence of a neck bruit does not exclude the possibility of a
significant carotid bifurcation lesion - focal ipsilateral carotid
bruits in symptomatic patients has a sensitivity of 63% and a
specificity of 61% for high-grade carotid stenosis (range, 70%-99%).</p>
<p>Screening of the general population is not indicated. Screening
should be considered for patients with:</p>
<ul>
<li><p>Evidence of clinically significant peripheral vascular disease
regardless of age</p></li>
<li><p>Patients aged &gt;65 years with a history of one or more of the
following atherosclerotic risk factors:</p>
<ul>
<li><p>CAD</p></li>
<li><p>Smoking</p></li>
<li><p>Hypercholesterolemia</p></li>
</ul></li>
<li><p>In general, the more risk factors present, the higher the yield
of screening should be expected.</p></li>
</ul></li>
<li><p><strong>US findings that confirm disease</strong></p>
<ul>
<li><p>50-69% stenosis of ICA - Low sensitivity for 50-69% stenosis - a
negative ultrasound in symptomatic patients necessitates
additional imaging</p>
<ul>
<li>PSV 125-229 cm/sec</li>
<li>EDV 40-100</li>
<li>Internal/Common Carotid PSV Ratio 2-4</li>
</ul></li>
<li><p>70-99% stenosis of ICA</p>
<ul>
<li><p>PSV &gt;/= 230 cm/sec</p></li>
<li><p>EDV &gt;100 (EDV &gt; 140 cm/sec most sensitive for stenosis &gt;80%)</p></li>
<li><p>Internal/Common Carotid PSV Ratio &gt; 4</p></li>
</ul></li>
<li><p>Velocity-based estimation of carotid artery stenosis may need to
be adjusted in certain circumstances</p>
<ul>
<li><p>Higher velocities in women than in men</p></li>
<li><p>Higher velocities in the presence of contralateral carotid
artery occlusion.</p></li>
</ul></li>
<li><p>High carotid bifurcation, severe arterial tortuosity, extensive
vascular calcification, and obesity may also reduce the accuracy
of DUS imaging</p></li>
</ul></li>
<li><p><strong>Other Imaging Modalities</strong></p>
<ul>
<li><p>CTA</p>
<ul>
<li><p>Pro - fast, sub-millimeter spatial resolution, visualize
surrounding structures</p></li>
<li><p>Con - cost, contrast exposure</p></li>
</ul></li>
<li><p>MRA</p>
<ul>
<li><p>Pro - no contrast administered; analyze plaque morphology</p></li>
<li><p>Con - Does not visualize calcium in plaque; overestimates
the degree of stenosis (False positive for 50-69% to be read
as &gt;70%)</p></li>
</ul></li>
<li><p>Catheter-based digital subtraction imaging (DSA)</p>
<ul>
<li><p>Still considered by many the gold-standard imaging modality</p></li>
<li><p>Reserved for individuals with conflicting less-invasive
imaging or those considered for CAS</p></li>
<li><p>Con - cost and risk of stroke</p></li>
</ul></li>
</ul></li>
</ol>
</div>
<div id="management" class="section level2" number="2.3">
<h2><span class="header-section-number">2.3</span> Management</h2>
<div id="optimal-medical-therapy" class="section level3" number="2.3.1">
<h3><span class="header-section-number">2.3.1</span> <strong>Optimal medical therapy</strong></h3>
<p><strong>Hypertension</strong></p>
<ul>
<li><p>Lowering blood pressure to a target &lt;140/90 mmHg by lifestyle
interventions and anti-hypertensive treatment is recommended in
individuals who have hypertension with asymptomatic carotid
atherosclerosis or those with TIA or stroke after the hyper-acute
period.</p></li>
<li><p>Each 10-mm Hg reduction in blood pressure among hypertensive
patients decreases the risk for stroke by 33%.</p></li>
</ul>
<p><strong>Diabetes</strong></p>
<ul>
<li>Glucose control to nearly normoglycemic levels (target hemoglobin
A1C &lt;7%) is recommended among diabetic patients to reduce
microvascular complications and, with lesser certainty,
macrovascular complications other than stroke.</li>
</ul>
<p><strong>Lipid abnormalities</strong></p>
<ul>
<li><p>Risk of stroke decreased by &gt;15% for every 10% reduction in serum
LDL in patients with known coronary or other atherosclerosis</p></li>
<li><p>Statin agents are recommended targeting LDL of 100 mg/dL, for those
with coronary heart disease or symptomatic atherosclerotic disease,
and LDL of 70 mg/dL for very high-risk persons with multiple risk
factors</p></li>
</ul>
<p><strong>Smoking</strong> - Physician counseling is an important and effective
intervention that reduces smoking in patients by 10% to 20%</p>
<p><strong>Antithrombotic therapy</strong> - There is no evidence to suggest that
antiplatelet agents other than aspirin have improved benefit in
asymptomatic patients with carotid atherosclerosis</p>
</div>
<div id="carotid-endarterectomy" class="section level3" number="2.3.2">
<h3><span class="header-section-number">2.3.2</span> <strong>Carotid endarterectomy</strong></h3>
<p><strong>Timing</strong></p>
<ul>
<li><p>Recommendations on when to operate after a stroke</p>
<ul>
<li><p>Acute stroke with a fixed neurologic deficit of &gt;6h duration -
When the patient is medically stable, less than or equal to 2
weeks after the stroke is preferable to a longer delay</p></li>
<li><p>Consider urgent intervention in a medically stable patient with
mild-moderate neurologic deficit, if there is a significant area
of ischemic penumbra at risk for progression</p></li>
<li><p>Stroke in evolution (fluctuating / evolving neuro deficit) or
crescendo TIA (repetitive transient ischemia w improvement
between events) - If neuro status is not stabilized by medical
intervention consider urgent CEA</p></li>
<li><p>CEA is preferred to CAS based on an increased embolic potential
of carotid lesions that present in this fashion</p></li>
</ul></li>
<li><p>What is the only emergent indication for CEA?</p>
<ul>
<li>Crescendo TIAs or a stroke in evolution with a surgically
correctable lesion that is identified</li>
</ul></li>
</ul>
<p><strong>Intraoperative Techniques</strong></p>
<ul>
<li><p>General concepts</p>
<ul>
<li>Patch angioplasty or eversion endarterectomy are recommended
rather than primary closure to reduce the early and late
complications of CEA (GRADE 1, Level of Evidence A).</li>
</ul></li>
<li><p>Neuromonitoring/Shunting options during a carotid endarterectomy</p>
<ul>
<li><p>Local anesthesia with direct neuro monitoring - the patient is
awake and moving to command throughout the case. Though improved
neuromonitoring has not been shown to reduce MI rate with CEA</p></li>
<li><p>Stump pressure Clamp the inflow and place butterfly attached to
a-line tubing into the internal carotid If stump pressure is &gt;
40 mmHg can proceed, if &lt; 40 place shunt</p></li>
<li><p>EEG Neuromonitoring - EEG tech places neuromonitoring, monitored
by intraop tech and neurologist remotely, generally clamp ICA
for 3 minutes before proceeding, if any deficits unclamp, await
normalization of EEG then proceed</p></li>
<li><p>Non-selective shunting - shunt all carotids</p></li>
</ul></li>
<li><p>Techniques to reach internal carotid lesions that are high?</p>
<ul>
<li><p>Nasotracheal intubation will help extend the neck to reach
higher lesions</p></li>
<li><p>Divide posterior belly of digastric to reach high lesions with
care to watch for glossopharyngeal</p></li>
<li><p>Styloidectomy</p></li>
<li><p>Mandible subluxation with assistance from ENT if previous
techniques fail.</p></li>
</ul></li>
<li><p>What is the best technique for a patient with a kinked internal
carotid artery?</p>
<ul>
<li><p>Eversion carotid endarterectomy will allow you to reduce the
redundancy</p></li>
<li><p>Otherwise, no advantage has been shown between eversion or
patch, both can be shunted</p></li>
</ul></li>
<li><p>Discuss nerve injuries – where you would encounter these and what
deficit would be seen</p>
<ul>
<li><p>Hypoglossal Just above the bifurcation of the carotid artery
Will see tongue deviation to the side of injury</p></li>
<li><p>Glossopharyngeal High dissections under digastric Difficulty
swallowing, aspiration risk, can be devastating</p></li>
<li><p>Vagus Adjacent and lateral to carotid, injury occurs with
carotid clamping, Hoarseness is noted as RLN is a branch off of
vagus</p></li>
<li><p>Marginal Mandibular (Off of facial nerve) Retraction at the
angle of the jaw for high dissections Leads to the corner of lip
drooping, can be confused with a neuro deficit following the
case</p></li>
</ul></li>
</ul>
<p><strong>Postoperative Complications</strong></p>
<ul>
<li><p>What to do if neuro deficits following your carotid endarterectomy</p>
<ul>
<li><p>If in OR – perform duplex, if normal open wound and shoot
cerebral angiogram</p></li>
<li><p>If in Recovery or on the floor – many would consider CTA first
vs duplex to look for thrombosis</p></li>
</ul></li>
<li><p>Risk factors and how to manage hyperperfusion syndrome?</p>
<ul>
<li><p>Defined as an ipsilateral headache, hypertension, seizures, and
focal neurological deficits can present 2-3 days out from
surgery</p></li>
<li><p>Patients with uncontrolled hypertension are at risk for
hyperperfusion syndrome, clinical practice guidelines by SVS
recommend strict BP control following CEA, maintain a pressure
less than 140/80</p></li>
</ul></li>
</ul>
<p><strong>Long term complications and follow up</strong></p>
<ul>
<li><p>Recommend f/u US at &lt;/=30 days. &gt;/= 50% stenosis requires further
imaging.</p></li>
<li><p>Contralateral stenosis</p>
<ul>
<li><p>The risk of progression for moderate stenosis at the initial
surveillance to severe stenosis can be as high as five times</p></li>
<li><p>Requires post-operative surveillance.</p></li>
</ul></li>
</ul>
</div>
<div id="carotid-artery-stenting" class="section level3" number="2.3.3">
<h3><span class="header-section-number">2.3.3</span> Carotid Artery Stenting</h3>
<ul>
<li><p>In patients aged &gt;70 undergoing CAS the risk of stroke was the
highest, presumably due to calcific disease in the arch</p>
<ul>
<li><p>Lesion-specific characteristics are thought to increase the risk
of cerebral vascular events after CAS and include a “soft”
lipid-rich plaque identified on noninvasive imaging, extensive
(15 mm or more) disease, a pre-occlusive lesion, and
circumferential heavy calcification</p></li>
<li><p>This can be reduced, but not eliminated, by using flow-reversal
embolic protection rather than distal filter protection</p></li>
</ul></li>
<li><p>Limited data on CAS in asymptomatic patients - currently is not
supported by guidelines or considered reimbursable</p></li>
<li><p>Consider CAS in symptomatic patients with &gt;50% stenosis who are poor
candidates for CEA due to severe uncorrectable medical comorbidities
and/or anatomic considerations (h/o ipsilateral neck dissection or
XRT, contralateral vocal cord paralysis, lesions that extend
proximally to the clavicle or distal to C2)</p></li>
<li><p>Transfemoral Approach vs Transcarotid approach</p>
<ul>
<li>ROADSTER Trial - single arm study with flow reversal for
cerebral protection. Suggest lower rates of post-op stroke</li>
</ul></li>
<li><p>Post-op follow up - Dual-platelet therapy should be continued for 1
month after the procedure, and aspirin should be continued
indefinitely</p></li>
</ul>
</div>
<div id="management-of-uncommon-disease-presentations" class="section level3" number="2.3.4">
<h3><span class="header-section-number">2.3.4</span> Management of uncommon disease presentations</h3>
<ul>
<li><p>Occluded Carotid What to do for occluded carotid?</p>
<ul>
<li>Leave it alone</li>
</ul></li>
<li><p>What if occluded carotid is still causing TIAs?</p>
<ul>
<li><p>External carotid endarterectomy and ligation of internal</p></li>
<li><p>The addition of oral anticoagulation is likely to reduce the
rate of recurrent CVA</p></li>
</ul></li>
<li><p>What if the patient has severe vertebrobasilar insufficiency and
carotid artery disease?</p>
<ul>
<li>Should undergo carotid revascularization first to improve flow</li>
</ul></li>
<li><p>What about tandem lesions in the carotid in a symptomatic patient,
carotid bulb and carotid siphon lesion (high ICA)? How should you
treat this?</p>
<ul>
<li>Treat carotid bulb first, likely the embolic source</li>
</ul></li>
<li><p>Carotid artery dissection</p>
<ul>
<li><p>Patients with carotid dissection should be initially treated
with antithrombotic therapy (antiplatelet agents or
anticoagulation) (GRADE 1, Level of Evidence C).</p></li>
<li><p>Patients who remain symptomatic on medical therapy may be
considered for intervention. Although data are insufficient to
make firm recommendations, the committee unanimously agreed that
balloon angioplasty and stenting is currently preferred over
open surgery after failed medical management (GRADE 2, Level of
Evidence C)</p></li>
</ul></li>
<li><p>Simultaneous coronary and carotid disease</p>
<ul>
<li><p>Patients with symptomatic carotid stenosis will benefit from CEA
before or concomitant with CABG. The timing of the intervention
depends on the clinical presentation and institutional
experience (GRADE 1, Level of Evidence B).</p></li>
<li><p>Patients with severe bilateral asymptomatic carotid stenosis,
including stenosis and contralateral occlusion, should be
considered for CEA before or concomitant with CABG (GRADE 2,
Level of Evidence B)</p></li>
</ul></li>
</ul>
</div>
</div>
<div id="prospective-trials---must-reads" class="section level2" number="2.4">
<h2><span class="header-section-number">2.4</span> Prospective Trials - MUST READS</h2>
<ol style="list-style-type: decimal">
<li><p>Asymptomatic Carotid Atherosclerosis Study (ACAS)</p>
<ul>
<li><p>Compared medical management with CEA in asymptomatic patients
with &gt; 60% stenosis</p></li>
<li><p>5-year stroke and death rate was 5.1% vs 11%</p></li>
<li><p>In women, the benefit of CEA was not as certain as 5y stroke and
death rates were 7.3% vs. 8.7%</p></li>
<li><p>This was pre statin and clopidigrel era</p></li>
</ul></li>
<li><p>North American Symptomatic Carotid Endarterectomy Trial (NASCET)</p>
<ul>
<li><p>Compared medical management vs CEA for symptomatic patients with
moderate (50-69%) and severe stenosis (&gt;70%)</p></li>
<li><p>Only moderate impact for patients with moderate stenosis
(50-69%)</p></li>
<li><p>Symptomatic patients with &gt;70 % stenosis benefited from CEA, at
18 months 7% major stroke in surgical arm, and a 24% stroke rate
in medical arm. 29% reduction in 5-year risk of stroke or death</p>
<ul>
<li>Patients with severe &gt;70% stenosis had such a dramatic
effect the trial was stopped early for this subset and all
referred for endarterectomy</li>
</ul></li>
<li><p>No benefit is shown in symptomatic patients with &lt; 50% stenosis</p></li>
<li><p>European studies have shown similar results</p>
<ul>
<li><p>ACST = ACAS</p></li>
<li><p>ECST = NASCET.</p></li>
</ul></li>
</ul></li>
<li><p>Carotid Revascularization Endarterectomy versus Stenting Trial
(CREST)</p>
<ul>
<li><p>Compared CEA vs. CAS in both symptomatic and asymptomatic
patients.</p></li>
<li><p>Composite endpoint of 30-day stroke, MI, death equivalent
between CEA and CAS</p></li>
<li><p>CAS had a significantly higher incidence of stroke and death
than CEA and CEA higher incidence of MI</p></li>
<li><p>Subanalyses identified that older patients (&gt;70y) had better
outcomes after CEA than CAS, the QOL impact of stroke was more
significant than that of MI, and anatomic characteristics of
carotid lesions (longer, sequential, remote) were predictive of
increased stroke and death after CAS</p></li>
<li><p>Unfortunately, this study provides a benchmark to strive for,
but no other large trials have achieved these results.</p></li>
</ul></li>
<li><p>ROADSTER</p>
<ul>
<li><p>Single arm feasibility trial of transcarotid carotid stenting</p></li>
<li><p>The results of the ROADSTER trial demonstrate that the use of
the ENROUTE Transcarotid NPS is safe and effective at preventing
stroke during CAS. The overall stroke rate of 1.4% is the lowest
reported to date for any prospective, multicenter clinical trial
of CAS.</p></li>
</ul></li>
<li><p>Trials to look out for in the next few years</p>
<ul>
<li><p>CREST-2 - multicenter, randomized controlled trial is underway
that is evaluating revascularization against modern intensive
medical management</p></li>
<li><p>ACT-1 and ACST-2- the role of intervention in asymptomatic
patients, designed to compare the early and long-term results of
CEA vs CAS and best medical management</p></li>
<li><p>ROADSTER-2 - TCAR</p></li>
</ul></li>
</ol>

</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="index.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="references.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/adam-mdmph/VS-Board-Review/edit/BRANCH/01-cerebrovascular.Rmd",
"text": "Edit"
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": ["_main.pdf"],
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "subsection"
}
});
});
</script>

</body>

</html>
